This site is intended for healthcare professionals
Alopecia areata learning zone
Alopecia areata Learning Zone
Declaration of sponsorship Pfizer

WCD 2023 congress highlights on alopecia areata

Declaration of sponsorship Pfizer
Read time: 30 mins
Last updated:20th Jul 2023
Published:11th Jul 2023
In this section

The changing landscape and new molecules for the treatment of alopecia areata

By Veena Angle

The 25th World Congress of Dermatology 2023 was held in Singapore from 3–8 July. This article is the first in a series of three covering discussions on the management of alopecia areata (AA) at the congress.

New therapeutic options and strategies

Until last year, systemic corticosteroids, cyclosporine, and methotrexate were the mainstay of treatment paradigms in moderate to severe alopecia. The landscape has changed since last year, with two Janus Kinase (JAK) inhibitors baricitinib and ritlecitinib approved by the FDA for treating moderate to severe AA. Subject to the accessibility of the new therapies, patients with moderate AA can be treated with JAK inhibitors and other systemic immunotherapies. In severe AA, JAK inhibitors have replaced conventional treatments with or without oral minoxidil and intralesional corticosteroids. Other systemic immunotherapies may be used with or without oral minoxidil and intralesional corticosteroids as a second line of treatment.

Dr Ruaa Al Harithy of the Dermatology Department, Security Forces Hospital, Riyadh, Saudi Arabia emphasized the ineffectiveness of topical and sublingual administration of JAK inhibitors in treating AA based on clinical studies1. A meta-analysis (PROSPERO: CRD 42022303007) comparing baricitinib, ritlecitinib, and brepocitinib showed similar efficacy and tolerability for oral JAK inhibitors in treating AA, whereas topical or sublingual administration lacked efficacy2. Currently, the clinical decision on using JAK inhibitors is primarily dictated by FDA approval, cost and accessibility of the drugs.

Dr Jerry Shapiro, Professor of Dermatology at New York University School of Medicine in the United States, also supported using JAK inhibitors in severe AA, and switching from tofacitinib to baricitinib3. Tofacitinib has been approved for use in rheumatoid arthritis but is frequently used off-label in treating alopecia4.

In 2022 and 2023, the FDA approved the first systemic therapies for AA, both JAK inhibitors

Data from pivotal trials of JAK inhibitors

Baricitinib was the first JAK inhibitor approved by the FDA for adults with severe AA in June 20225. It is the first systemic therapy approved for use in AA, thus extending treatment to the entire body rather than specific areas. The FDA approval for baricitinib is supported by efficacy and safety data from two phase 3 randomised controlled trials (BRAVE-AA1 and BRAVE-AA2) in patients with a Severity of Alopecia Tool (SALT) score of 50 or higher6.

On 23 June 2023, the FDA approved the second JAK inhibitor, ritlecitinib, for severe AA in adults and adolescents (≥12 years) based on the phase 2b/3 ALLEGRO trial results. The ALLEGRO trial showed an acceptable safety profile and efficacy for ritlecitinib up to 48 weeks in patients aged 12 years and over with at least 50% scalp hair loss7. Efficacy was also observed in the regrowth of eyebrows and eyelashes, which are otherwise difficult to treat1.

Dr Melissa Piliang, Dermatologist at the Cleveland Clinic in the United States, presented a late-breaker session on the long-term efficacy of ritlecitinib up to 24 months in an integrated analysis of the ALLEGRO phase 2b/3 and long-term phase 3 clinical studies in alopecia areata (ALLEGRO-LT/NCT04006457)8. Patients rolled over from the ALLEGRO-2b/3 trial and de novo patients receiving ritlecitinib 50 mg (with or without 200 mg loading dose) demonstrated clinically meaningful and sustained long-term clinician and patient-reported efficacy through month 24.

Safety of JAK inhibitors and FDA black box warning

The FDA issued a black box warning about the increased risk of heart-related severe events, cancer, blood clots and death with JAK-inhibitors used to treat chronic inflammatory conditions last year. However, experts at WCD 2023 were sceptical of the warning in relation to the treatment of AA9. Dr Al Harithy highlighted that the black box warning was issued based on major cardiovascular adverse events (MACE) and malignancies in patients with rheumatoid arthritis who were aged 50 years or older with at least one cardiovascular (CV) risk factor1,10, in contrast to AA patients who are typically younger and without CV risk. Dr Sergio Vano-Galvan, Head of the Trichology Unit at Ramón y Cajal Hospital, Madrid, also shared that serious adverse events were rare in patients with AA treated with JAK inhibitors11.

Regardless, Dr Shapiro highlighted the importance of selecting suitable candidates for therapy with JAK inhibitors and monitoring patients during treatment with laboratory tests3. Treatment should not be initiated in case of abnormalities in the blood counts and liver enzymes. Good candidates for treatment of AA with JAK inhibitors are patients aged 18-50 years with no comorbidities, SALT scores of more than 50 and the current episode lasting for less than 5 years with active disease.

While positive clinical trial results and long-term data form the basis for recent approvals of JAK inhibitors for treating alopecia areata, it is important to choose patients suitable for these therapies

JAK inhibitors for alopecia areata: From bench to bedside and beyond

By Veena Angle

The 25th World Congress of Dermatology 2023 was held in Singapore, from 3-8 July. This is the second in a series of three articles covering discussion related to the management of alopecia areata (AA) at the congress.

Dr Alessandra Anzai, University of Sao Paulo, Brazil, documented the journey of immunotherapies in AA from the bench to the bedside12. Early genome-wide association studies identified innate and adaptive immunity as contributing to AA pathology13. Subsequent research stimulated development of the first systemic treatment for AA, with the JAK inhibitor baricitinib being approved by the US FDA in 2022. AA is treatable through inhibiting the JAK 1 and/or 3 pathways.

Dr Sergio Vano-Galvan, Head of the Trichology Unit at Ramón y Cajal Hospital, Madrid, presented on novel therapeutic approaches in AA. “A new era has arrived in alopecia areata with the use of JAK inhibitors,” said Dr Vano-Galvan referring to US FDA and EMA approvals for baricitinib in treating severe AA14. For severe AA, American guidelines propose JAK inhibitors as first-line treatment15. Given the results observed in his patients, Vano-Galvan expects JAK inhibitors to become a standard-of-care for the treatment of AA.

The US FDA has approved baricitinib (JAK 1/2) and ritlecitinib (JAK 3) for the treatment of AA. Ritlecitinib is expected to receive EMA approval in late 2023; deu-ruxolitinib (JAK 1/2) is predicted to be approved by the FDA and EMA in 202411.

Areas in AA that warrant further studies include:

  • Gut microbiota can impact on immunoregulation in autoimmune diseases such as AA; fecal microbial transplantation could be a treatment option for AA16
  • Genetic abnormalities, resulting in abnormalities of the hair follicle, may predispose certain people to develop AA17

Conclusions from clinical studies on JAK inhibitors for alopecia areata

Clinical trials demonstrate that more than one-third of patients with AA on baricitinib can achieve ≥80% hair regrowth18. Up to 40% of patients with AA on ritlecitinib can achieve ≥80% hair regrowth19.

On the safety profile of the JAK inhibitors, Dr Vano-Galvan emphasised that the serious adverse events mentioned in the black box warning were not frequently observed in patients with AA. In his clinical experience, adverse events observed following use of JAK inhibitors in AA tend to be mild, and included upper respiratory tract infections, headaches, nasopharyngitis, nausea and acne11.

On baricitinib trials, Dr Vanos-Galvan made these observations11:

  • A higher proportion of patients with severe AA compared to very severe AA achieved SALT score ≤20 after 36 weeks, indicating that disease severity may influence the prognosis and time to response on baricitinib
  • Baricitinib significantly improved the response rate in patients with SALT ≤20, regardless of the duration of the current episode
  • After 52 weeks, achievement of meaningful improvement in eyebrow and eyelash regrowth occurred across all response subgroups (including those who did not respond with growth in scalp hair), with greater response rates in patients with SALT score ≤20
  • Almost 40% of partial responders after 52 weeks can achieve clinically meaningful scalp hair regrowth at 104 weeks if treatment is continued
  • There is no loss in the efficacy of baricitinib over time, with approximately 90% of patients who responded at 52 weeks being able to maintain clinically meaningful scalp hair regrowth through to one-hundred and four weeks
  • Down titration of baricitinib in patients with severe AA is likely to cause a relapse

Dr Anzai interpreted clinical trial data on JAK inhibitors for AA as follows12:

  • Oral formulations of JAK inhibitors are more effective than placebo, whereas topical formulations are less effective
  • There is no significant difference in the efficacies of baricitinib, ritlecitinib and brepocitinib in clinical trials
  • There is no significant difference in efficacy of ruxolitinib and tofacitinib in non-randomised clinical trials
  • An equal proportion of patients treated with JAK inhibitors show complete response, partial response, or no response
  • The response time for treatment of AA with JAK inhibitors can take 6–12 months
  • Relapse is common after discontinuation of JAK inhibitors
  • Long-term maintenance therapy raises concerns of side effects and toxicity

Strategies to improve therapy effectiveness for alopecia areata

Dr Vano-Galvin shared his positive experience with novel therapies in the AA setting, including imiquimod as an enhancer of immunotherapy with diphencyprone20, oral mini-pulses of dexamethasone (0.1 mg/kg per day for two consecutive days each week), a combination of oral dexamethasone and topical diphencyprone, corticosteroid injections in the hair bulb, and oral etrasimod11.

Dr Vano-Galvan expressed disappointment with the results of the phase 2 trial of dupilumab (monoclonal antibody targeting IL4 and IL13) in AA. After 48 weeks of dupilumab treatment, 32.5%, 22.5% and 15% achieved SALT30, SALT50 and SALT75, respectively. Baseline IgE >200 IU/ml levels may serve as biomarkers for a positive response to treatment21.

A novel and promising agent, LH-8, is being investigated in a placebo-controlled phase 2/3 clinical trial in patients aged 2–18 years22.

Strategies that can increase the efficacy of JAK inhibitors for AA include increasing treatment dose, or combination therapy comprising JAK inhibitors with methotrexate or corticosteroids, oral minoxidil, or clarithromycin. In case of poor patient response, switching between JAK inhibitors with different pathways can be an option12. For example, in patients with AA who partially respond or experience a recurrence of hair loss after an initial favorable response to tofacitinib therapy can benefit from switching to baricitinib23.

From registration trials to combinations and novel therapies, the treatment armamentarium for alopecia is growing

Clinical trial and real-world data on managing alopecia areata

By Veena Angle

The 25th World Congress of Dermatology 2023 was held in Singapore, from 3–8 July. This is the third in a series of three articles covering discussion related to the management of alopecia areata (AA) at the congress.

New data from BRAVE-AA1, BRAVE-AA2, ALLEGRO-LT

Assistant Professor Maryanne M Senna from the Lahey Hospital and Medical Center, Harvard Medical School, Boston, United States, presented patient-reported outcomes (PRO) from the phase 3 clinical trials, BRAVE-AA1 (NCT03570749) and BRAVE-AA2 (NCT03899259) for scalp, eyebrow, and eyelash, in patients with severe AA treated with baricitinib.

  • There was continuous improvement in scalp, eyebrow and eyelash PROs over 52 weeks
  • For eyelash hair regrowth, response rates were 24.3% for baricitinib 2 mg, and 40.8% for baricitinib 4 mg
  • For eyebrow hair regrowth, response rates for baricitinib 2 mg and 4 mg were 21.3% and 40.4%, respectively

These results are significant for patients more concerned about the cultural significance of facial hair than scalp hair loss24.

Associate Professor Brett King from Yale School of Medicine, New Haven, United States, presented post hoc analyses from BRAVE-AA1/2 for duration of hair loss and clinically meaningful hair regrowth. There was a trend toward better treatment response in patients with a shorter duration of hair loss, regardless of baseline disease severity. Thus, early intervention may confer greater treatment efficacy for patients with severe AA treated with baricitinib25.

Professor Rodney Sinclair of the Department of Medicine, University of Melbourne, Australia, presented interim results from the ALLEGRO-LT phase 3 study evaluating the long-term safety and efficacy of ritlecitinib in patients with AA up to month 36. The study included patients over 12 years of age with ≥25% hair loss rolled over from the ALLEGRO phase 2a and 2b/3 studies, and patients who had not participated in either study. At data cutoff, 78.3% of patients reported adverse events (AE) that were mild or moderate in severity. The most frequent treatment emergent AEs were headache (16.3%), acne (11.6%), nasopharyngitis (8.5%), SARS-CoV-2 test positive (13.4%), and urticaria (8.1%). Rates of serious AEs, severe AEs, and treatment discontinuations were 4.0%, 5.4%, and 4.9%, respectively. At month 24, 69.6% achieved SALT scores of ≤20, 62.5% of patients had SALT scores of ≤10. Regrowth of eyebrow and eyelash hair was observed in 54.1% and 63.9% of patients, respectively26.

Phase 3 clinical trials of different treatment options for alopecia are also considering impact on patient wellbeing and other patient-reported outcomes

Research on treating alopecia areata in routine clinical practice

The abstracts and free communications sessions were an opportunity for dermatologists to describe their experiences managing AA in routine clinical practice. Therapies for managing patients with AA were presented, including apremilast27 and low-dose oral minoxidil28, which are options in settings with limited access to approved drugs.

Dr Yuping Tan of the Department of Dermatovenereology, West China Hospital, Sichuan University, presented an analysis of treatment with baricitinib in his patients with AA conducted over 1.5 years. Patients were treated with glycyrrhizin and/or diprosone intramuscular injection combined with 2% or 5% minoxidil tincture, and oral baricitinib 2/4 mg. Hair regrowth was visible after 2 months in 41.3% of patients and by week 24, 35% of the patients achieved 80% hair regeneration. AEs were mild and did not warrant discontinuation of treatment29.

Dr Huw Rees of Sinclair Dermatology, Melbourne, Australia, presented data from the pilot phase of the Global Registry of Alopecia Areata Disease Severity and Treatment Safety (GRASS). The registry is an international collaborative network of patient registries collecting harmonised epidemiological, socioeconomic and treatment data. Currently, national registries have been established in Australia, Italy, and Ireland. The registry enrolled 489 patients in the first six months, who had a median SALT score of 20 (IQR = 86.5%). Scalp involvement was reported in 78.5% (95% CI 71.9–83.9). Most had patchy AA (59.3%; 95% CI 52.0–66.3), while 7.7% (95% CI 4.4–12.4) and 16.0% (11.1–21.9) had alopecia totalis or alopecia universalis, respectively. The group is seeking interest from dermatologists from across the globe, aiming to recruit diverse ethnic populations30.

The results of longer-term treatment show that hair regrowth continues to improve for adults with severe alopecia areata on baricitinib

References

  1. Al Harithy R. Managing Alopecia Areata in 2023. Presented at the World Congress of Dermatology 2023, 3-8 July. Singapore. Egyptian Women’s Dermatologic Society Session.
  2. Yan D, Fan H, Chen M, Xia L, Wang S, Dong W, et al. The efficacy and safety of JAK inhibitors for alopecia areata: A systematic review and meta-analysis of prospective studies. Front Pharmacol. 2022;13:950450.
  3. Shapiro J. JAK inhibitors for alopecia areata. Presented at the World Congress of Dermatology 2023, 3-8 July. Singapore. American Hair Research Society Session.
  4. Ibrahim O, Bayart CB, Hogan S, Piliang M, Bergfeld WF. Treatment of Alopecia Areata With Tofacitinib. JAMA Dermatol. 2017;153(6):600-602.
  5. FDA, 2022. FDA Approves First Systemic Treatment for Alopecia Areata [press release]. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-first-systemic-treatment-alopecia-areata. Accessed 7 July 2023.
  6. King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, et al. Two Phase 3 Trials of Baricitinib for Alopecia Areata. N Engl J Med. 2022;386(18):1687-1699.
  7. King B, Zhang X, Harcha WG, Szepietowski JC, Shapiro J, Lynde C, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial. Lancet. 2023;401(10387):1518-1529.
  8. Piliang M. Long-term efficacy of ritlecitinib up to Month 24: integrated analysis of the ALLEGRO phase 2b/3 and long-term phase 3 clinical studies in alopecia areata (AA). Presented at the World Congress of Dermatology 2023, 3-8 July. Singapore. Late-breaker session.
  9. Lebwohl M. Why we should use JAK inhibitors: Risk-Benefit Ratios. Presented at the World Congress of Dermatology 2023, 3-8 July. Singapore. Expert Forum.
  10. Thorley J. FDA expands JAK inhibitors warning: going beyond the data? The Lancet Rheumatology. 2021;3(11):e757.
  11. Vano-Galvan S. Alopecia areata: Novel therapeutic approaches. Presented at the World Congress of Dermatology 2023, 3-8 July. Singapore. Symposium SY10A.
  12. Anzai A. Pathobiology of alopecia areata: Recent progress and major open questions. Presented at the World Congress of Dermatology 2023, 3-8 July. Singapore. Symposium SY10A.
  13. Petukhova L, Duvic M, Hordinsky M, Norris D, Price V, Shimomura Y, et al. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature. 2010;466(7302):113-117.
  14. Freitas E, Guttman-Yassky E, Torres T. Baricitinib for the Treatment of Alopecia Areata. Drugs. 2023;83(9):761-770.
  15. Meah N, Wall D, York K, Bhoyrul B, Bokhari L, Sigall DA, et al. The Alopecia Areata Consensus of Experts (ACE) study: Results of an international expert opinion on treatments for alopecia areata. J Am Acad Dermatol. 2020;83(1):123-130.
  16. Kang Y, Cai Y, Zhao Y, Yang Y. The gut microbiome and Alopecia areata: Implications for early diagnostic biomarkers and novel therapies. Front Nutr. 2022;9:979876.
  17. Jadeja SD, Tobin DJ. Autoantigen Discovery in the Hair Loss Disorder, Alopecia Areata: Implication of Post-Translational Modifications. Front Immunol. 2022;13.
  18. Kwon O, Senna MM, Sinclair R, Ito T, Dutronc Y, Lin CY, et al. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2). Am J Clin Dermatol. 2023;24(3):443-451.
  19. King B, Zhang X, Harcha WG, Szepietowski JC, Shapiro J, Lynde C, et al. A plain language summary on ritlecitinib treatment for adults and adolescents with alopecia areata. Immunotherapy. 2023.
  20. Díaz-Guimaraens B, Saceda-Corralo D, Hermosa-Gelbard Á, Moreno-Arrones Ó M, Dominguez-Santas M, Suarez-Valle A, et al. Imiquimod-enhanced immunotherapy with diphencyprone for patients with alopecia areata. Dermatol Ther. 2022;35(7):e15516.
  21. Guttman-Yassky E, Renert-Yuval Y, Bares J, Chima M, Hawkes JE, Gilleaudeau P, et al. Phase 2a randomized clinical trial of dupilumab (anti-IL-4Ralpha) for alopecia areata patients. Allergy. 2022;77(3):897-906.
  22. NCT03240627. Efficacy and Safety of LH-8 in Paediatric Alopecia Areata (AA). Available at: https://www.clinicaltrials.gov/study/NCT03240627. Accessed 10 July 2023.
  23. Kazmi A, Moussa A, Bokhari L, Bhoyrul B, Joseph S, Chitreddy V, et al. Switching between tofacitinib and baricitinib in alopecia areata: A review of clinical response. J Am Acad Dermatol. 2023.
  24. Senna M. Patient-reported outcomes for scalp, eybrow and eyelash involvement in patients with severe alopecia areata treated with baricitinib: 52-week results from two phase 3 clinical trials. Presented at the World Congress of Dermatology 2023. Singapore. Free communications session (FC27).
  25. King B. Duration of current episode of alopecia areata influences prognosis during treatment with Baricitinib in patients with severe AA. Presented at the World Congress of Dermatology 2023. Singapore. Free communications session (FC27).
  26. Sinclair R. Long-term safety and efficacy of ritlecitinib in patients with alopecia areata: interim results from the ALLEGRO-LT phase 3, open-label study. Presented at the World Congress of Dermatology 2023. Singapore. Free communications session (FC27).
  27. Ghate S. Apremilast - an effective, alternative in the treatment of alopecia areata, oophiases, totalis, universalis. Presented at the World Congress of Dermatology 2023. Singapore. Free communications session (FC28).
  28. Shah A. Low dose oral minoxidil in non-scarring alopecia: A retrospective study of 128 patients. Presented at the World Congress of Dermatology 2023. Singapore. Free communications session (FC28).
  29. Tan Y. Oral JAK inhibitor Baricitinib for alopecia areata: A real-world study. Presented at the World Congress of Dermatology 2023. Singapore. Free communications session (FC28).
  30. Rees H. The Global Registry of Alopecia Areata Disease Severity and Treatment Safety (GRASS) International: Results from the pilot. Presented at the World Congress of Dermatology 2023. Singapore. Free communications session (FC27).
Welcome:
Register
Updates in your area
of interest
Articles your peers
are looking at
Bookmarks
saved
Days to your
next event